Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term immunogenicity and boostability after different primary PrEP regimens with purified chick-embryo cell rabies vaccine with/without Japanese encephalitis vaccine in adults
2015-000382-31Phase 3Completed
- Sponsor
- GSK
- Start
- May 2015
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of rabies vaccine purified chick embryo cell in rabies and Japanese encephalitis (JE) (2 arms), sponsored by GSK. Primary endpoints: Long-term rabies immunogenicity and Boostability of rabies immune response. Started May 2015; status: completed.
02
Drugs
rabies vaccine purified chick embryo cell
03
Conditions
rabiesJapanese encephalitis (JE)
Beyond the preview
Go deeper on 2015-000382-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000382-31.